Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: Relationship to clinicopathological variables

Cell Biochemistry and Function

Volumn 25, Issue 4, 2007, Pages 433-441

  Işlekel, Hüray ^a   Oktay, Gülgün ^a   Terzi, Cem ^a   Canda, Aras Emre ^a   Füzün, Mehmet ^a   Küpelioǧlu, Ali ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Colorectal cancer; Matrix metalloproteinase 3; Matrix metalloproteinase 9; Tissue inhibitors of matrix metalloproteinase 1

Indexed keywords

GELATIN; GELATINASE B; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; ZYMOGRAPHY;

AGED; COLON; COLORECTAL NEOPLASMS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROSPECTIVE STUDIES; RECTUM; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 34447500091     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1325     Document Type: Article

References (27)

1. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 2004; 10: 8229-8234.
2. McLeod HL, Murray GI. Tumour markers of prognosis in colorectal cancer. Brit J Cancer 1999; 79: 191-203.
3. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189: 300-308.
4. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000; 36: 1621-1630.
5. Waas ET, Hendriks T, Lome RMLM, Wobbes T. Plasma levels of matrix metalloproteinase-2 and Tissue Inhibitors of Metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 2005; 48: 700-710.
6. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metast Rev 2004; 23: 101-117.
7. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and-9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005; 87: 287-297.
8. Mook ORF, Frederiks WM, Van Noorden CJF. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004; 1705: 69-89.
9. Fujimoto N, Ward RV, Shinya T, Iwata K, Yamashita K, Hayakawa T. Interaction between tissue inhibitor of metalloproteinases-2 and progelatinase A: immunoreactivity analysis. Biochem J 1996; 313: 827-833.
10. Baker EA, Leaper DJ. Measuring gelatinase activity in colorectal cancer. EJSO 2002; 28: 24-29.
11. Waas ET, Lomme RMLM, DeGroot J, Wobbes T, Hendricks T. Tissue levels of active matrix metalloproteinase-2 and-9 in colorectal cancer. Brit J Cancer 2002; 86: 1876-1883.
12. Waas ET, Wobbes T, Lome RMLM, DeGroot J, Ruers T, Hendriks T. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Brit J Surgy 2003; 90: 1556-1564.
13. Langenskiöld M, Holmdahl L, Falk P, Ivarsson ML. Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. Int J Colorectal Dis 2005; 20: 245-252.
14. Inuzuka K, Ogata Y, Nagase H, Shirouzu K. Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. J Surg Res 2000; 93: 211-218.
15. Bodey B, Bodey B, Jr., Siegel SE, Kaiser HE. Prognostic significance of matrix metalloproteinase expression in colorectal carcinomas. In Vivo 2000; 14: 659-666.
16. Garbett EA, Reed MWR, Brown NJ. Proteolysis in colorectal cancer. J Clin Pathol: Mol Pathol 1999; 52: 140-145.
17. Baker EA, Leaper DJ. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Eur J Cancer 2003; 39: 981-988.
18. Baker EA, Bergin FG, Leaper DJ. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Brit J Surg 2000; 87: 1215-1221.
19. Moran A, Iniesta P, Garcia-Aranda C, et al. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. Oncol Rep 2005; 13: 115-120.
20. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical excision. Histopathological study of lateral tumor spread and surgical excision. Lancet 1986; 2: 996-999.
21. Fleming ID. 2002. American Joint Committee on Cancer. Colon and rectum. In AJCC Cancer Staging Manual, 6th edn, Cooper JS, Henson DE (eds). Lippincott-Raven Publishers: Philadelphia; 113-124.
22. Wiechelman KJ, Braun RD, Fitzpatrick JD. Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation. Anal Biochem 1988; 175: 231-237.
23. Haussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980; 102: 196-202.
24. Roeb E, Arndt M, Jansen B, Schumpelick V, Matern S. Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1,-3, and-13 gene expression by multiplex PCR in colorectal carcinomas. Int J Colorectal Dis 2004; 19: 518-524.
25. Zeng ZS. Cohen AM, Zhang ZF, Stetler-Stevenson WG, Guillem JG. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastasis. Clin Cancer Res 1995; 1: 899-906.
26. Joo YE, Seo KS, Kim J, et al. Role of tissue inhibitors of metalloproteinases (TIMPs) in colorectal carcinoma. J Korean Med Sci 1999; 14: 417-423.
27. Lu X, Levy M, Weinstein IB, Santella RM. Immunologic quantification of levels of tissue inhibitor of metalloproteinase-1 in human colon cancer. Cancer Res 1991; 51: 6231-6235.